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Figure III. The CoMSIA maps of the CoMSIA-2 (A) the CoMSIA-EFF (B) model. Cl-IB-MECA 68 was used as a representative 
ligand for the hydrophobic map. The visualization of the CoMSIA map has been performed using the StDev*Coefficient 
mapping option contoured by contribution. Favored and disfavored levels fixed at 80% and 20%, respectively, were used for 
all fields. In the CoMSIA result, the hydrophobic maps are shown in yellow for regions tolerating groups of increased 
hydrophobic interactions and white for regions unfavoring hydrophobic groups and favoring hydrophilic groups to increase 
the binding affinity to the A3AR.  
 
Supporting results. 
 
Generation of data sets. To achieve a statistically significant 3D-QSAR model, the following conditions are considered generally 
standard: (1) a minimum range of three log units for compound binding affinity, (2) ~20 compounds (corresponding to ~5 compounds 
per principal component) for model generation, and (3) even distribution of the biological activities of the compounds.22 Biological 
data was derived from several studies14–21 that used the same assay conditions and radiolabeled competitive binding agonist, [125I]-I-
AB-MECA. Thus, the combined data set exhibited a four-log-unit difference between the highest (72: pKi = 9.55) and the lowest (71: 
pKi = 5.37) binding affinities, with other affinities evenly distributed in that range. 
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3D-QSAR modeling. The cross-validated q2 is generally proving to be a much better indicator than r2 of the reliability of a given 
predictions. The q2 is generally somewhat lower, and often much lower than the conventional r2 value. According to the CoMFA 
manual, the 95% confidence limit for a q2 in CoMFA is ~0.3, so statistical significance is unlikely to be the issue. Since one or more 
unique compounds whose target values are badly predicted are involved in the analysis, cross-validation highlights the potential risks 
involved in relying on the properties of a single compound, affecting the dramatic decrease of q2 value. Thus, we calculated q2 value 
of each model and increased its value up to >0.5 through omitting an outlier in the residual plot. 
   To examine the predictability of the training set, preliminary 3D-QSAR studies were carried out for all 91 compounds on the basis 
of the binding affinity for the A3AR subtype with SAMPLS to improve the efficiency and the speed of the 3D-QSAR. A further leave-
one-out cross-validation implemented in PLS analysis was performed, in which each compound was systematically excluded from the 
training data set. To reduce cross-correlated brown noise in the data matrix, region focusing was applied to each model for a selective 
weighting of the grid points in a region. Only CoMFA (CoMFA-RF1/2) models resulted in an increase of r2 value; other models did 
not (data not shown). In concert with q2, the predictive r2 is used to evaluate the overall performance of a model by comparing the 
accuracy of a series of predictions with the experimentally determined data for a given target property. The power of each model to 
make predictions for the A3AR agonists was validated by using the external test sets. Comparison of the experimentally observed and 
predicted pKi values at the A3AR further confirmed the predictive ability of each model. The residuals between corresponding values 
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of the experimental and predicted binding affinity for each compound were less than one log unit, and all test set compounds followed 
the regression trend line.  
   Although traditional CoMFA models exhibited statistical significance comparable to CoMSIA models in the present case, 
additional hydrophobic and H-bonding fields from CoMSIA give more information on the binding site and receptor activation, which 
may prove useful for the design of agonists with higher binding affinity. Since the different lattice spacing did not affect the statistical 
parameters of CoMSIA, one model for the relative efficacy at the A3AR was generated with the default value of 2.0 Å lattice spacing. 
Since the active conformation of adenosine is unknown, the same alignment of the A3AR-bound conformation was used for the 
generation of CoMSIA-EFF model. 
   The steric and electrostatic maps from the CoMFA-RF1 model and the hydrophobic and H-bonding maps from the CoMSIA-2 
model were represented as contour maps for each property in Figure 3. The CoMSIA steric and electrostatic maps agreed with the 
CoMFA steric and electrostatic maps (Figure III-A). 
 
Comparison of 3D-QSAR with docking models and activation mechanisms. Brief docking results of hA3AR follows. The amine 
of the N6 substituent in proximity to N250 (6.55) was H-bonded with the hydroxyl group of S247 (6.52). The 2′-OH group of the 
ribose ring was involved in H-bonding with the side chain of Q167 (EL2). The 3′-OH group formed a HB with the side chain of H272 
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(7.43), consistent with our A3 neoceptor model.26 The 5′-amide NH group formed an intramolecular HB with the 4′-O atom and was 
close to T94 (3.36), and the 5′-carbonyl oxygen atom formed a HB with S271 (7.41). The aromatic portion of the N6-benzyl moiety 
showed additional pi-pi stacking interaction with the aromatic ring of F168 (EL2). 
   Previously, the activation of the human A3AR by several adenosine derivatives was studied in intact CHO cells stably expressing 
this receptor.19 SAR studies showed that small N6-alkyl groups increased binding affinity, while bulkier aliphatic rings lowered both 
efficacy and binding affinity at the hA3AR. For example, efficacy was 100% (Ki of hA3: 6.4 nM), 97% (Ki of hA3: 72 nM), 76% (Ki of 
hA3: 73 nM), and 49% (Ki of hA3: 411 nM) for N6-cyclobutyl–, N6-cyclopentyl–, N6-cyclohexyl–, and N6-cyclooctyl–substituted 
adenosine, respectively. Although selectivity for the hA3AR was obtained with the introduction of a 3-iodobenzyl substituent at the N6 
position, N6-(3-iodobenzyl)–substituted adenosine exhibited partial agonistic effects at the same receptor. This result is consistent with 
the presence of the map that requires a less sterically bulky group at the N6 position in the CoMSIA-EFF model. Unlike in the N6-
binding site, in the binding site for C2 substituents, the presence of sterically bulky aliphatic groups, i.e. those with an increased size 
and chain length (compounds 3 to 7), were tolerated with respect to maximal efficacy at the hA3AR, correlating with the map that 
required a large bulky group from the CoMSIA-EFF model.  
   In addition, as shown in the steric and hydrophobic maps (Figure III-B), large green steric and yellow hydrophobic contours 
indicating tolerance of steric bulk and hydrophobicity, respectively, around the N6-aromatic group matched well with the hydrophobic 
binding site surrounded by F168 (EL2), M177 (5.38), and F182 (5.43). 
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   The appearance of red polyhedra at the meta position of the phenyl ring of the N6 group was consistent with the observation that 
the electron-withdrawing groups having partial negative charge at this position in compounds 64 (N6-3-Cl-benzyl) and 65 (N6-3-I-
benzyl) improved binding affinity in comparison with N6-benzyl in 62 or N6-3-methylbenzyl in 63. Blue CoMSIA-2 contour maps 
requiring a positively charged group at the C2 position of the adenine ring predicted positively charged C2 substituents to increase the 
binding affinity at the A3AR. 
   The H-bonding field map was very useful because of the importance of H-bonding of adenosine analogues in binding to the 
hA3AR, especially at the ribose-binding position and at the exocyclic amine of the adenine ring. An H-bonding field was detected in 
the CoMSIA-EFF model near the N6 and 5′ positions. An H-bonding donor contour around the N6 position was directed toward the 
side chain of S247 (6.52), which formed a HB with the N6H in the docking complex. Both a region requiring a HB donor at the 5′-NH 
and a region requiring an acceptor at the 5′-CO group from the CoMSIA-EFF model were located at the side chains of T94 (3.36) and 
S271 (7.41) in the putative binding site. 
 
   In a previous pharmacophore study, A3AR-selective agonists required more H-bonding ability than did the pharmacophore of 
A3AR-selective antagonists.23 This pharmacophore study is also consistent with the receptor docking of the agonist, which showed 
additional H-bonding to the ribose moiety, and with the H-bonding map from the CoMSIA model.  
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   Although there is no global active-state model, local conformational changes have been proposed.23 In agonist-binding domains, 
compared with antagonist-binding domains, additional interactions were present at the kink site of TM6 and near TM7. The distinct 
binding sites might have differing effects on the conformational change of activation. 
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Table I. Binding affinities of adenosine derivatives (training set) at human (unless noted, r – rat) A1, A2A, and A3ARs expressed in 
CHO cells (expressed as Ki value or percent inhibition at 10 µM unless noted) and relative maximal agonist efficacy at 10 µM at the 
A3AR. Unless noted, R1, R2 = H; R3 = OH; R4 = O; R5 = CH2OH.   
R4
OHR3
R5 N
N
NHR1
N
N R2
 
 
Substitution AR binding affinity (nM)a or % displ. at 10 µM; A3AR efficacy # 
 
R1 R2 R3 R4 R5 Ki (hA1AR) Ki (hA2AAR) Ki (hA3AR)  Efficacy (%)b 
Ref. 
1      310  700 290      ND) 39 
2  Cl    7.5±1.4 630±220 87±24     100±7) 14 
3  MeO    155±32 970±310 156±37    75.2±5.1) 16 
4  EtO    2640±540 360±139  568±205    99.1±4.2)  16 
5  i-PrO    16.0% 927±204 457±154     101±5) 16 
6  PenO    2430±620 6.9±1.3 222±68   92.8±13.4) 16 
7  i-PenO    4410±1150 222±89 84.2±8.4    108±10) 16 
8  HexO    1830±340 156±89 124±28    43.7±6.3) 16 
9  PhO    5140±1110 44±12 364±96     32.2±3.5) 16 
10  BnO    642±79 585±155 117±8     16.9±3.9) 16 
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Substitution AR binding affinity (nM)a or % displ. at 10 µM; A3AR efficacy # 
 
R1 R2 R3 R4 R5 Ki (hA1AR) Ki (hA2AAR) Ki (hA3AR)  Efficacy (%)b 
Ref. 
11  PhEtO    221±57 9.3±2.9 54.2±14.3    70.7±2.7 16 
12  2-MePhEtO    396±83 17.4±7.4  214±47    7.3±6.0 16 
13  3-MePhEtO    295±8 41.6±22.0  242±55    70.9±3.9 16 
14  4-MePhEtO    1250±250 118±95  470±81    95.5±15.1 16 
15  2-MeOPhEtO    490±114 274±142  940±354    3.6±6.7 16 
16  3-MeOPhEtO    246±34 32.1±1.6  231±53   85.1±5.8 16 
17  4-MeOPhEtO    288±22 64.3±7.8  105±20    91.9±9.2 16 
18  2-ClPhEtO    366±33 17.9±6.1  144±22    1.4±2.7 16 
19  3-ClPhEtO    372±116 11.5±5.3  41.0±7.8    31.0±7.0 16 
20  4-ClPhEtO    331±51 58.5±8.0  116±23    69.0±6.3 16 
21  1-NaphEtO    220±18 3.8±1.4  205±19    12.8±5.9 16 
22  2,2-diPhEtO    38.5% 310±119  53.6±10.4    0.0±0.6 16 
23  PhEtNH    530±88 62.0±17.6  310±163    72.0±3.2 16 
24     EtNHCO  6.8±2.4 2.2±0.6  16.0±5.4    100 16 
25   S   5240±740 5740±980 445±54    0 17 
26 Me     5970±2030 17%, 10-5 M  9.3±0.4    96±3 15 
27 MeO     223±32 (r)  >10,000 (r) 28.6±4.7    107±13 19 
28 Et     4.9±0.2 (r) 8900±770 (r) 4.7±1.9    102±6 19 
29 i-Pr     1.9±0.1 (r) 2030±510 (r) 18.3±5.5    111±4 19 
30 (CH3)2CH) 2CH     3.8±0.8 (r) 2170±490 (r)  3760±840    21±2 19 
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Substitution AR binding affinity (nM)a or % displ. at 10 µM; A3AR efficacy # 
 
R1 R2 R3 R4 R5 Ki (hA1AR) Ki (hA2AAR) Ki (hA3AR)  Efficacy (%)b 
Ref. 
31 cyclopentyl     1.8±0.5 820±216  72±12    99±6 16 
32 (S)-endo-2-norbornyl     0.34±0.06 (r)  915±299    23±10 19 
33 cycloPrMe     0.8±0.3 (r) 1370±410 (r) 10.2±4.1   108±4 19 
34 Ph     3.3±0.3 (r) 663 (r)  14.9±3.1   102±9 19 
35 Bn     77.8±6.5 2180±670 41.3±5.3    55±3 14 
36 PhEt     12.9±2.1 676±39 2.1±0.4    84±5 14 
37 PhEtO     225±45 (r) >10,000 (r)  88.7±7.4    73±6 19 
38 2-MeBn     59.6±14.3 (r)  24.1±1.8 (r) 47.2±10.8    100±3 19 
39 2-MeOBn     36±2 (r) 761±460 (r) 32.5±4.6    81±8 19 
40 2-ClBn     17±3 (r) 93±16 (r) 17.3±3.2    95±1 19 
41 3-ClBn     45±3 (r) >10,000 (r) 4.4±1.7    80±3 19 
42 4-ClBn     61±3 (r) 5120±1230 (r) 47.5±4.1    96±2 19 
43 (R)-1-Ph-2-Pr     2.04 859  8.7±0.9    102±6 14 
44 S)-1-Ph-2-Pr     75  7780  68±12    97±3 14 
45 (1S,2R)-2-Ph-1-cycloPr     30.1±6.1 2250±430 0.63±0.17    117±9 14 
46 (1R, 2S)-2-Ph-1-cycloPr     15.6±1.7 2340±330 24.1±10.9    87±4 14 
47 (R)-2-Ph-1-Pr     4.0±1.3  325±85 9.1±0.3    99±4 14 
48 2,2-diPhEt     49.9±16.2  510±49 3.9±0.7    0 14 
49 3,5-diMeOPh-2-MePhEt     168±29 153±26 106±22    0 14 
50 9-fluorenemethyl     14.0±4.0 145±26 0.91±0.38    99±6 14 
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Substitution AR binding affinity (nM)a or % displ. at 10 µM; A3AR efficacy # 
 
R1 R2 R3 R4 R5 Ki (hA1AR) Ki (hA2AAR) Ki (hA3AR)  Efficacy (%)b 
Ref. 
51  4-CO2HEt PhEtNH   EtNHCO 1570±460 8.8±1.6  114±16    98±5 16 
52  Cl  S    4.9±1.3    64±18 17 
53 Me CN    69.8±4.4 23%  3.4±0.8    101±7 15 
54 Me NH2    484±22 15%  39.0±2.4    98±3 15 
55 Me N3    232±10 22.9% 10.8±3.1    83.7 21 
56 Me 4-MePhC≡C    2560±610 29% 1.5±0.4    9.4 21 
57 Me 4-PenPhC≡C    5.2% 6.2% 33.3±0.2    0 21 
58 Me 4-Ph-triazole    35.8% 4.6% 14.9±1.7    14.0 21 
59 Me 4-Bn-triazole    589±55 19.9% 9.5      0 21 
60 Me 4-(4-PrO-Ph)-triazole    35.5% 14.2% 25.2±2.6    31.2 21 
61 Me   S  359±69 26% 10.3±0.7    60±11 17 
62 Bn   S  597±8 2110±740 155±33    87±7 17 
63 3-MeBn   S  179±19 3610±1110 13.9±5.7    48±9 17 
64 3-ClBn   S  91.8±6.0 995±206 6.7±0.4    62±3 17 
65 3-IBn   S  45.9±2.1 575±75 1.9±0.4    60±4 17 
66 Naphth-1-yl-Me   S  129±23 206±15 42.2±13.0    72±4 17 
67  Cl  S MeNHCO 89.2±11.7 158±29 0.40±0.06    100±5 18 
68 3-IBn Cl   MeNHCO 1240±320 5360±2470 1.4±0.3    100 14 
69 3-IBn  NH2  MeNHCO 3080±380 67% 137±41    37±5 20 
70 3-IBn  CH2NH2  MeNHCO 52% 6% 1690±330    17±2 20 
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Substitution AR binding affinity (nM)a or % displ. at 10 µM; A3AR efficacy # 
 
R1 R2 R3 R4 R5 Ki (hA1AR) Ki (hA2AAR) Ki (hA3AR)  Efficacy (%)b 
Ref. 
71 3-IBn Cl N3  MeNHCO 70% 29% 4270±1400    0 20 
72 Me Cl  S MeNHCO 1330±240 20% 0.28±0.09    119±12 18 
73 Me Cl  S diMeNCO 10% 12% 1500±1300    8.3±5.9 18 
74 Me Cl  S cycloPrNHCO 47.8±5.7 2770±580 2.82±1.03    98±8 18 
75 Me Cl  S i-PenNHCO 4070±1220 14% 1.63±0.17    92±4 18 
76 Me Cl  S 3-F-BnNHCO 67% 41% 17.4±3.8    57±2 18 
77 Me Cl  S 2-(3-F-Ph)EtNHCO 15% 30% 85.6±35.6    11±5 18 
78 Me Cl  S 3,3-diPhPrNHCO 20% 15% 415±16    0.1±2.8 18 
79 cycloPr Cl  S MeNHCO 37.3±2.5 4890±380 2.24±1.21    99±3 18 
80 cycloPr Cl  S EtNHCO 3.2±0.3 604±110 0.67±0.07    97±3 18 
81 cycloPr Cl  S 4-Bn-piperidineCO 32% 33% 4020±740    0 18 
82 cycloPen Cl  S EtNHCO 2.0±2 149±29 2.83±0.63    95±3 18 
83 2-MeBn Cl  S EtNHCO 75.8±2.5 429±97 2.50±1.10   112±9 18 
84 2-MeBn Cl  S diMeNCO 0% 22.5% 632±70    9.1±0.4 18 
85 3-IBn Cl  S EtNHCO 144±55 292±120 0.89±0.18    100±6 18 
86 3-IBn Cl  S cycloPrNHCO 92.0±10.9 326±23 2.96±1.03    87±4 18 
87 3-IBn Cl  S cycloBuNHCO 126±2 549±78 18.2±13.4    100±3 18 
88 3-IBn Cl  S 4-(4-F-Ph)-PiperazineCO 24% 12% 1440±830    96±10 18 
89 3-IBn Cl  S 3-ClBnNHCO 1710±340 28% 308±148    33±9 18 
90 3-IBn Cl  S PhEtNHCO 20% 11% 433±141    7.1±2.7 18 
91 3-IBn Cl  S 3,3-diPhPrNHCO 5% 3% 343±48    31±14 18 
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a)  AR experiments were generally performed using adherent CHO cells stably transfected with cDNA encoding the human ARs. Percent 
activation of the human A3AR was determined at 10 µM. Binding at human A1 and A2AARs in this study was carried out using [3H]R-PIA 
(N6-[(R)-phenylisopropyl]adenosine) or [3H]CGS 21680 (2-[p-(2-carboxyethyl)phenyl-ethylamino]-5′-N-ethylcarboxamidoadenosine) as a 
radioligand. Binding at human A3AR was carried out using [125I]I-AB-MECA as a radioligand. Values from the present study are expressed 
as mean ± s.e.m., n = 3-5.   
b)  Percent A3AR activity at 10 µM, relative to the ability of 10 µM Cl-IB-MECA to inhibit adenylyl cyclase.   
ND: not determined.   
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Table II. Measured and predicted binding affinities and relative maximal agonist efficacy of adenosine derivatives at human A3ARs 
in the training set. Refer to Figure 1A for structures of the adenosine derivatives.  Affinities were previously reported.14-21,39 
 
Predicted binding affinities (pKi) 
# 
pKi at 
hA3AR CoMFA-2 CoMFA-1 CoMFA-RF2 CoMFA-RF1 CoMFA-HB2 CoMFA-HB1 CoMSIA-2 CoMSIA-1 
Efficacy 
(%) 
Predicted 
Eff. (%) 
1 6.54 7.36 7.35 7.16 7.25 7.47 7.20 7.76 7.71 100 107 
2 7.06 7.53 7.43 7.33 7.24 7.52 7.28 7.51 7.43 100 97.5 
3 6.81 6.96 6.80 6.87 6.72 6.78 6.79 6.82 6.79 75.2 103 
4 6.25 6.54 6.50 6.60 6.39 6.51 6.69 6.49 6.52 99.1 99.5 
5 6.34 6.13 6.28 6.26 6.27 6.51 6.65 6.20 6.25 101 102 
6 6.65 6.79 6.87 6.74 6.92 6.71 6.79 6.85 6.86 92.8 79.3 
7 7.07 6.84 6.91 6.71 6.91 6.67 6.85 6.74 6.74 108 89.2 
8 6.91 6.83 6.86 6.75 6.92 6.73 6.80 6.93 6.92 43.7 66.3 
9 6.44 6.54 6.44 6.50 6.55 6.52 6.65 6.18 6.21 32.2 34.3 
10 6.93 6.91 6.96 6.99 6.81 6.85 6.79 6.97 6.91 16.9 5.90 
11 7.27 6.87 6.91 6.73 6.92 6.83 6.96 6.93 6.96 70.7 67.0 
12 6.67 6.75 6.75 6.73 6.80 6.86 6.82 6.89 6.89 7.30 38.9 
13 6.62 6.73 6.78 6.72 6.82 7.01 6.94 7.00 7.01 70.9 65.1 
14 6.33 6.76 6.71 6.74 6.78 6.82 6.81 6.82 6.83 95.5 77.1 
15 6.03 6.18 6.17 6.62 6.44 6.45 6.45 6.39 6.39 3.60 20.8 
16 6.64 6.85 6.82 6.81 6.82 6.75 6.77 6.57 6.58 85.1 72.1 
17 6.98 7.02 6.96 6.77 6.92 7.11 6.89 6.88 6.88 91.9 78.6 
18 6.84 6.81 6.75 6.76 6.74 6.86 6.80 6.97 6.98 1.40 12.5 
19 7.39 7.04 7.01 6.79 6.91 6.78 6.79 7.16 7.17 31.0 34.5 
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20 6.94 6.92 6.88 6.74 6.89 7.06 6.80 6.82 6.84 69.0 65.8 
21 6.69 6.72 6.70 6.69 6.78 6.79 6.78 6.71 6.70 12.8 26.9 
22 7.27 7.27 7.28 7.11 7.27 7.18 7.13 7.31 7.33 0 2.12 
23 6.51 6.35 6.37 6.58 6.42 6.36 6.28 6.33 6.28 72.0 55.4 
24 7.80 7.60 7.56 7.26 7.47 7.55 7.58 7.52 7.51 100 107 
25 6.35 7.51 7.40 7.45 7.19 7.43 7.70 7.92 8.10 0 71.0 
26 8.03 7.77 7.89 7.57 7.94 8.11 7.95 8.20 8.17 96.0 101 
27 7.54 7.67 7.70 7.39 7.58 7.48 7.50 7.40 7.44 107 98.7 
28 8.33 7.98 7.94 7.82 8.07 7.45 7.54 7.84 7.83 102 89.9 
29 7.74 7.58 7.51 7.50 7.53 7.64 7.29 7.64 7.61 111 91.9 
30 5.42 5.17 5.13 5.28 5.24 5.74 5.85 5.51 5.53 21.0 18.7 
31 7.14 7.42 7.31 7.43 7.21 7.54 7.18 7.32 7.32 99.0 100 
32 6.04 6.04 5.93 6.14 6.22 6.73 6.50 5.79 5.74 23.0 20.8 
33 7.99 7.68 7.80 7.61 7.88 7.73 7.80 7.95 7.97 108 105 
34 7.83 7.74 7.83 7.53 7.87 7.15 7.58 7.90 7.93 102 102 
35 7.38 7.76 7.68 7.70 7.58 7.73 7.74 7.59 7.68 55.0 93.9 
36 8.68 8.65 8.78 8.67 8.86 8.55 8.45 8.68 8.69 84.0 92.9 
37 7.05 7.01 6.87 7.17 6.89 7.24 7.26 6.79 6.81 73.0 63.1 
38 7.33 7.29 7.43 7.04 7.56 7.27 7.50 7.34 7.37 100 93.0 
39 7.49 8.00 7.82 7.71 7.97 7.55 7.51 7.56 7.59 81.0 86.5 
40 7.76 7.81 7.82 7.51 7.89 7.64 7.47 7.85 7.84 95.0 110 
41 8.36 8.02 7.94 7.85 7.89 7.83 7.78 7.71 7.72 80.0 92.4 
42 7.32 7.81 7.67 7.75 7.59 7.75 7.72 7.47 7.51 96.0 99.0 
43 8.06 7.89 7.90 7.98 7.98 8.06 7.77 7.98 7.98 102 89.1 
44 7.17 7.11 7.11 7.51 7.31 7.29 7.30 7.31 7.37 97.0 92.3 
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45 9.20 9.16 9.14 9.12 9.21 8.62 8.48 8.92 8.95 117 119 
46 7.62 7.86 7.72 8.17 7.81 7.80 7.71 7.88 7.86 87.0 78.3 
47 8.04 8.43 8.26 8.60 8.33 8.62 8.33 8.42 8.49 99.0 90.8 
48 8.41 8.22 8.28 7.94 8.25 8.05 8.13 8.27 8.18 0 2.38 
49 6.97 6.89 6.89 7.15 7.12 6.91 7.05 7.19 7.13 0 -3.84 
50 9.04 8.99 8.94 8.85 9.04 8.86 8.76 9.03 8.94 99.0 41.8 
51 6.94 6.85 6.73 7.48 7.04 6.49 6.73 6.88 6.83 98.0 90.7 
52 8.31 7.74 7.70 7.66 8.09 7.54 7.86 7.74 7.87 64.0 61.2 
53 8.47 8.42 8.47 8.29 8.22 8.21 8.41 8.19 8.19 101 103 
54 7.41 7.69 7.62 7.54 7.64 7.48 7.31 7.31 7.32 98.0 99.1 
55 7.97 8.13 8.08 7.80 7.94 8.06 8.00 7.83 7.81 83.7 81.4 
56 8.82 8.41 8.68 8.37 8.16 8.36 8.28 7.53 7.47 9.40 10.6 
57 7.48 7.26 7.47 8.34 7.99 8.06 8.14 7.57 7.55 0 -3.63 
58 7.83 7.62 7.81 8.00 7.50 7.74 7.91 7.82 7.75 14.0 19.5 
59 8.02 8.00 8.13 8.21 7.70 8.05 8.04 8.09 8.01 0 -6.68 
60 7.60 7.37 7.58 7.97 7.50 7.65 7.73 7.61 7.52 31.2 24.7 
61 7.99 7.93 7.93 7.88 7.87 7.88 8.05 8.35 8.55 60.0 64.2 
62 6.81 7.60 7.63 7.71 7.48 7.76 7.92 7.72 8.08 87.0 68.7 
63 7.86 7.82 7.86 7.84 7.76 7.86 8.09 7.77 8.05 48.0 65.1 
64 8.17 7.81 7.87 7.83 7.79 7.85 8.08 7.86 8.13 62.0 66.8 
65 8.72 7.76 7.87 7.78 7.77 7.82 8.06 8.00 8.12 60.0 64.4 
66 7.37 7.41 7.34 7.43 7.27 7.57 7.92 7.53 7.71 72.0 3.63 
67 9.40 8.93 8.91 8.69 9.05 8.66 9.20 8.86 8.84 100 99.2 
68 8.85 8.23 8.46 7.91 8.56 8.48 8.40 7.62 7.54 100 90.8 
69 6.86 6.95 7.24 7.16 7.28 7.31 7.45 7.23 7.19 37.0 99.5 
 S17 
70 5.77 5.83 5.57 6.11 5.49 5.34 5.48 5.70 5.68 17.0 13.3 
71 5.37 5.85 5.62 6.32 5.35 5.28 5.51 5.32 5.28 0 -6.47 
72 9.55 9.45 9.37 9.24 9.52 9.35 9.34 9.37 9.36 119 94.6 
73 5.82 6.44 6.45 6.35 5.91 6.56 6.38 7.63 7.57 8.30 28.2 
74 8.55 8.74 8.76 8.81 8.64 8.87 8.64 8.93 8.95 98.0 108 
75 8.79 8.94 8.88 8.41 8.85 8.38 8.41 9.01 8.97 92.0 97.0 
76 7.76 7.51 7.46 7.81 7.34 7.37 7.46 7.42 7.46 57.0 48.0 
77 7.07 7.04 6.78 7.02 6.99 6.62 6.65 6.99 7.02 11.0 9.32 
78 6.38 6.39 6.18 6.31 6.28 6.24 6.02 6.71 6.73 0.10 17.1 
79 8.65 9.21 9.33 9.03 9.36 9.17 9.25 9.11 9.13 99.0 99.5 
80 9.17 9.13 9.08 9.14 9.07 9.05 8.82 9.02 9.01 97.0 105 
81 5.40 5.45 5.58 5.00 5.57 5.00 4.68 5.44 5.47 0 9.23 
82 8.55 8.83 8.56 8.95 8.61 9.05 8.57 8.75 8.79 95.0 107 
83 8.60 8.10 8.25 8.04 8.56 8.17 8.23 7.98 8.08 112 86.1 
84 6.20 5.63 5.82 5.57 6.08 6.54 6.15 6.38 6.44 9.10 10.4 
85 9.05 8.96 8.96 8.86 9.08 8.84 8.73 8.65 8.60 100 92.5 
86 8.53 8.91 8.90 8.83 8.73 8.95 8.95 8.93 8.83 87.0 112 
87 7.74 7.90 8.00 8.11 7.90 8.29 8.25 8.12 8.11 100 95.3 
88 5.84 5.88 6.10 6.00 5.81 6.01 5.74 5.90 5.90 96.0 94.8 
89 6.51 6.77 6.79 7.15 6.51 7.22 7.36 6.53 6.54 33.0 30.7 
90 6.36 6.32 6.42 6.37 6.47 6.53 6.46 6.42 6.41 7.10 3.88 
91 6.46 6.16 6.16 6.18 6.33 6.15 6.18 6.34 6.30 31.0 17.4 
 
The numbers in bold italics indicate outliers in the residual plots from the cross-validation analyses.  
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Table III. The binding affinities of 25 adenosine derivatives (test set) at human (unless noted, r – rat) A1, A2A, and A3ARs expressed in CHO cells (expressed as 
Ki value or percent inhibition at 10 µM) and relative maximal agonist efficacy at 10 µM at the A3AR. Unless noted, R1, R2 = H; R3 = OH; R4 = O; R5 = 
CH2OH.  
R4
OHR3
R5 N
N
NHR1
N
N R2
 
 
Substitution AR binding affinity (nM)a or % displ. at 10 µM; A3AR efficacy # 
 
R1 R2 R3 R4 R5 Ki (hA1AR) Ki (hA2AAR) Ki (hA3AR)  Efficacy (%)b 
Ref. 
92 3-IBn     7.4±1.7 135±22 5.8±0.4    46±8 15 
93 (S)-2-Ph-1-Pr     26.6±6.8 1120±260 38.8±4.1    98±6 14 
94 cyclooctyl     1.7±0.1 (r) 6200±1120 (r) 411±55    49±5 19 
95  3-ClBnO    27.4±3.9 228±66 71.6±24.6    16.2±3.8 16 
96  2-FPhEtO    331±22 58.1±24.9  77.8±13.5    44.5±5.1 16 
97  4-FPhEtO    467±100  56.8±16.3  112±16    73.4±5.2 16 
98  3,4-DiMeOPhEtO    469±118  30.3±2.8  863±313    66.5±3.7 16 
99  PhBuO    1100±230  243±166  251±80    19.3±6.2 16 
100  PhPenO    700±126  249±54  429±159    9.8±8.8 16 
101 Me 4-PrPhC≡C    45.4% 2.9% 4.5±0.9    0 21 
102 Me 4-Bu-triazol    848±76 23.0% 11.7±3.1    3.4 21 
103 Me 4-pyridinyl-triazol    1970±210 39.7% 10.3±1.5    11.4 21 
104 5-Cl-2-MeOBn CN    63.2±16.9 1260±190 2.76±0.51    29±6 15 
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105 PhEt   S  82.6±6.8 507±31 5.6±1.1    86±5 13 
106 3-IBn  N3  MeNHCO 64% 32% 2260±480    0 20 
107 Me Cl  S  629±168 4% 0.8±0.1     96±5 17 
108 Bn Cl  S  2280±180 47% 18.2±2.6    63±4 17 
109 2-MeBn Cl  S  853±133 3280±170 48.9±16.6    62±4 17 
110 3-IBn Cl  S  554±64 1190±290 3.2±0.9    32±7 17 
111 Me Cl  S 4-Bn-piperidineCO 10% 6% 3500±340    3.1±1.3 18 
112 cycloPr Cl  S cycloPrNHCO 4.6±0.3 325±13 5.56±1.77    85±4 18 
113 cycloPr Cl  S morpholineCO 25% 11% 4440±160    83±5 18 
114 cycloPen Cl  S MeNHCO 13.9±18 921±76 4.27±0.33    105±2 18 
115 2-MeBn Cl  S cycloPrNHCO 76.7±9.3 202±51 27.8±3.8    91±3 18 
116 3-IBn Cl  S MeNHCO 193±46 223±36 0.38±0.07    114±9 18 
 
 
a)  AR experiments were generally performed using adherent CHO cells stably transfected with cDNA encoding the human ARs. Percent 
activation of the human A3AR was determined at 10 µM. Binding at human A1 and A2AARs in this study was carried out using [3H]R-PIA 
or [3H]CGS 21680 as a radioligand. Binding at human A3AR was carried out using [125I]I-AB-MECA as a radioligand. Values from the 
present study are expressed as mean ± s.e.m., n = 3-5.   
b)  Percent A3AR activity at 10 µM, relative to the ability of 10 µM Cl-IB-MECA to inhibit adenylyl cyclase.   
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Figure I-A. 
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